Retraction to: Cancer Gene Therapy https://doi.org/10.1038/s41417-019-0098-6, published online 11 June 2019
The Editor-in-Chief has retracted this article at the authors’ request. After publication, the authors became aware that some images were misused in Fig. 6d, which resulted in image overlap between the PUMA-KD Control and Cabozantinib groups. The raw data are no longer available. Therefore, the authors have lost confidence in the conclusions drawn in the study.
Shida Yang, **aobing Zhang, Huiling Qu, Bo Qu and **aoxue Yin agree to this retraction. Hongmei Zhao has not responded to any correspondence from the editor or publisher about this retraction.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yang, S., Zhang, X., Qu, H. et al. Retraction Note: Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway. Cancer Gene Ther 29, 1806 (2022). https://doi.org/10.1038/s41417-022-00545-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41417-022-00545-3
- Springer Nature America, Inc.